Indeed, tumour cells with BRAF mutations are addicted to ERK1/2 signalling for repression of BIM 58 and pharmacological inhibition of ERK1/2 signalling induces strong increases in BIM expression in many contexts. The gene discussed is BCL2L11; the disease is neoplasm.